Expert perspectives
[Affiliates to insert drivers to local asset]
SELECT-PsA 1 clinical trial results
Listen to Dr. Frank Behrens discuss RINVOQ study results in patients with active psoriatic arthritis and an inadequate response to non-bDMARDs.1,2
SELECT-PsA 1 study explainer
Watch an overview of the study design and results.2
RINVOQ at work
Learn about the mechanism of action of upadacitinib.
Safety profile
Explore safety data from the SELECT Phase 3 clinical program.
Podcasts
month XX, 2021
[Podcast title placeholder]
[Affilates to add local podcasts]
XX mins
month XX, 2021
[Podcast title placeholder]
[Affilates to add local podcasts]
XX mins
RINVOQ Important Safety Information1
Please see the RINVOQ Summary of Product Characteristics for complete prescribing information.
[Insert local HUMIRA Important Safety Information]
Please see the HUMIRA Summary of Product Characteristics for complete prescribing information.
NOTE TO AFFILIATES: Consult local MRL regarding adding a link to the adalimumab SmPC in the main navigation area.
You may also be interested in
- RINVOQ [Summary of Product Characteristics]. AbbVie Deutschland GmbH & Co. KG.
- McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021;384(13):1227-1239. doi:10.1056/NEJMoa2022516